e19005 Background: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin cancer. The annual incidence for MCC, based on SEER database, was 0.6 cases per 100,000 in 2006 (0.15 cases per 100,000 in 1986), with slightly more males affected (60%). Due to its rarity, data on its clinico-pathological features and impact of therapy are limited. Aim: To characterize MCC based on immunohistochemical (IHC) features and serum levels of biochemical markers such as chromogranin A (CgA) and serotonin and select treatment options. Methods: This prospective pilot study included 7 patients (pts) since 2009 and their age, sex, primary site, IHC features and serum levels of biochemical markers, progression-free-survival (PFS) were recorded. Median of overall survival was not achieved. Results: Pts characteristics were: age 44–67 years (mean 57), male–female ratio = 4:3. Most common primary sites were extremities (5pts), lymphnode metastases from unknown primary (1pt) and genitals (1pt). IHC showed diffuse positivity for CgA (6pts), dot-like staining for cytokeratin 20 (7pts), synaptophysin (6pts), Ki-67 (40%-1pt, 50%-1pt, 60–70%-5pts). The tumors did not express vimentin, TTF1. Serum levels of Cg A (2pts) and serotonin (1pt) were above normal. Treatment: Local disease – surgery, either alone (1pt) or as part of multimodality plan (2pts); Locoregional disease – surgery plus chemotherapy (2pts) and chemotherapy alone (1pt); Distant disease – chemotherapy plus surgery (1pt). Median of PFS was 16 months.Two patients with improvement of biochemical markers continue to receive maintenance therapy with somatostatin (SST) analogues for 16 and 24 months with complete remission. Conclusions: SST analogues facilitates treatment of MCC without reducing quality of life and increase PFS in patients with high CgA serum level. In spite of recent advances in understanding the biology of MCC, many molecular mechanisms that influence behavior stills are unknown.